Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists

BACKGROUND: The long-acting muscarinic antagonist (LAMA) aclidinium was approved in Europe in 2012 to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). A post-authorization safety study was initiated to assess potential cardiovascular risks associated with LAMAs v...

Descripción completa

Detalles Bibliográficos
Autores principales: Rebordosa, Cristina, Plana, Estel, Rubino, Annalisa, Aguado, Jaume, Martinez, David, Lei, Alejhandra, Daoud, Sami, Saigi-Morgui, Nuria, Perez-Gutthann, Susana, Rivero-Ferrer, Elena
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356604/
https://www.ncbi.nlm.nih.gov/pubmed/35941901
http://dx.doi.org/10.2147/COPD.S363997

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9356604/
https://www.ncbi.nlm.nih.gov/pubmed/35941901
http://dx.doi.org/10.2147/COPD.S363997

Ejemplares similares